These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

549 related articles for article (PubMed ID: 24769036)

  • 1. Oxaliplatin salvage for recurrent ovarian cancer: a single institution's experience in patient populations with platinum resistant disease or a history of platinum hypersensitivity.
    Taylor SE; Beck TL; Krivak TC; Zorn KK; Kelley JL; Edwards RP
    Gynecol Oncol; 2014 Jul; 134(1):68-72. PubMed ID: 24769036
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxaliplatin-based combination chemotherapy is still effective for the treatment of recurrent and platinum-resistant epithelial ovarian cancer: results from a single center.
    Zhang G; Li XP; Liu BJ; Wang JL; Wang SJ; Cui H; Wei LH
    Chin Med J (Engl); 2013 Dec; 126(23):4477-82. PubMed ID: 24286410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxaliplatin is a safe alternative option for patients with recurrent gynecologic cancers after hypersensitivity reaction to Carboplatin.
    Kolomeyevskaya NV; Lele SB; Miller A; Riebandt GC; Blum BL; Odunsi KO; Frederick PJ
    Int J Gynecol Cancer; 2015 Jan; 25(1):42-8. PubMed ID: 25356535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.
    Wang Y; Herrstedt J; Havsteen H; DePoint Christensen R; Mirza MR; Lund B; Maenpaa J; Kristensen G
    BMC Cancer; 2014 Dec; 14():937. PubMed ID: 25494701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II trial of sorafenib alone or in combination with carboplatin/paclitaxel in women with recurrent platinum sensitive epithelial ovarian, peritoneal, or fallopian tube cancer.
    Schwandt A; von Gruenigen VE; Wenham RM; Frasure H; Eaton S; Fusco N; Fu P; Wright JJ; Dowlati A; Waggoner S
    Invest New Drugs; 2014 Aug; 32(4):729-38. PubMed ID: 24619298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevention of carboplatin-induced hypersensitivity reactions in women with ovarian cancer.
    Jerzak KJ; Deghan Manshadi S; Ng P; Maganti M; McCuaig JM; Bulter M; Oza A; Mackay HJ
    J Oncol Pharm Pract; 2018 Mar; 24(2):83-90. PubMed ID: 27856924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response rates to second-line platinum-based therapy in ovarian cancer patients challenge the clinical definition of platinum resistance.
    Lindemann K; Gao B; Mapagu C; Fereday S; Emmanuel C; Alsop K; Traficante N; ; Harnett PR; Bowtell DDL; deFazio A
    Gynecol Oncol; 2018 Aug; 150(2):239-246. PubMed ID: 29807697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single nedaplatin treatment as salvage chemotherapy for platinum/taxane-resistant/refractory epithelial ovarian, tubal and peritoneal cancers.
    Goto T; Takano M; Ohishi R; Iwasa N; Shimizu M; Hasegawa K; Nagao S; Fujiwara K
    J Obstet Gynaecol Res; 2010 Aug; 36(4):764-8. PubMed ID: 20666942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 2 study of oxaliplatin combined with continuous infusion topotecan for patients with previously treated ovarian cancer.
    Stein SM; Tiersten A; Hochster HS; Blank SV; Pothuri B; Curtin J; Shapira I; Levinson B; Ivy P; Joseph B; Guddati AK; Muggia F
    Int J Gynecol Cancer; 2013 Nov; 23(9):1577-82. PubMed ID: 24172094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine-oxaliplatin (GEMOX) as salvage treatment in pretreated epithelial ovarian cancer patients.
    Vici P; Sergi D; Pizzuti L; Mariani L; Arena MG; Barba M; Maugeri-Saccà M; Vincenzoni C; Vizza E; Corrado G; Paoletti G; Tomao F; Tomao S; Giannarelli D; Di Lauro L
    J Exp Clin Cancer Res; 2013 Aug; 32(1):49. PubMed ID: 23927758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
    Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
    Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bevacizumab toxicity in heavily pretreated recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancers.
    Martin JY; Urban RR; Liao JB; Goff BA
    J Gynecol Oncol; 2016 Sep; 27(5):e47. PubMed ID: 27329195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of platinum sensitivity and resistance by cyclosporin A in refractory ovarian and fallopian tube cancer patients: a phase II study.
    Chambers SK; Davis CA; Schwartz PE; Kohorn EI; Chambers JT
    Clin Cancer Res; 1996 Oct; 2(10):1693-7. PubMed ID: 9816118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous/intraperitoneal paclitaxel and intraperitoneal carboplatin in patients with epithelial ovarian, fallopian tube, or peritoneal carcinoma: a feasibility study.
    Nagao S; Iwasa N; Kurosaki A; Nishikawa T; Ohishi R; Hasegawa K; Goto T; Fujiwara K
    Int J Gynecol Cancer; 2012 Jan; 22(1):70-5. PubMed ID: 22146766
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer.
    van der Burg ME; Onstenk W; Boere IA; Look M; Ottevanger PB; de Gooyer D; Kerkhofs LG; Valster FA; Ruit JB; van Reisen AG; Goey SH; van der Torren AM; ten Bokkel Huinink D; Kok TC; Verweij J; van Doorn HC
    Eur J Cancer; 2014 Oct; 50(15):2592-601. PubMed ID: 25096168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.
    Armstrong DK; White AJ; Weil SC; Phillips M; Coleman RL
    Gynecol Oncol; 2013 Jun; 129(3):452-8. PubMed ID: 23474348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients.
    Dieras V; Bougnoux P; Petit T; Chollet P; Beuzeboc P; Borel C; Husseini F; Goupil A; Kerbrat P; Misset JL; Bensmaïne MA; Tabah-Fisch I; Pouillart P
    Ann Oncol; 2002 Feb; 13(2):258-66. PubMed ID: 11886003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.
    Rosa DD; Awada A; Mano MS; Selleslags J; Lebrun F; Gil T; Piccart MJ; D'Hondt V
    Arch Gynecol Obstet; 2008 Nov; 278(5):457-62. PubMed ID: 18273626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
    Herzog TJ; Monk BJ; Rose PG; Braly P; Hines JF; Bell MC; Wenham RM; Secord AA; Roman LD; Einstein MH; Drake RD; Childs BH
    Gynecol Oncol; 2014 Mar; 132(3):517-25. PubMed ID: 24476788
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.